Among patients with stages 4 and 5 CKD, denosumab exhibited a higher risk for emergently treated hypocalcemia versus oral bisphosphonates in those with CKD-MBD (1.53 versus 0.02 percent) than in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback